Just out at JNCI, we review 20 years of RCTs in myeloma for lessons in drug development.

Surprisingly, head-to-head trials were as likely to be successful as add-on trials.

academic.oup.com/jnci/advance... #mmsm #myeloma

Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.

Thanks David Russler-Germain + collabs

aacrjournals.org/clincancerre...

Just out @jama.com, led by Ian Liu we review 10 years of nononcology accelerated approvals

12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID

>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social

What steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting & identification?

👇 check out this figure from our @thelancethaem.bsky.social adverse event commission

www.thelancet.com/journals/lan... @broeckelmann.bsky.social

The latest in a trio of meta-analyses by Tobias, David & Kai just out at Molecular Therapy, on non-relapse mortality after bispecific antibodies in lymphoma & myeloma.

>70% of non-relapse deaths are due to infection.

Need to prioritise measurement, reporting, prophylaxis, early intervention.

Just out @jama.com

Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway

Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas

jamanetwork.com/journals/jam... @portalresearch.org

Delighted Piers Blombery joined us to discuss CAR transgenic T-cell lymphoproliferative neoplasms & all things post-CAR-T malignancies on Blood Cancer Talks, with a side helping of molecular haematology. We discuss Piers' recent NEJM paper plus recent MSKCC case w transgene integration into TP53.

Enticing data for axi-cel in high risk upfront DLBCL in ZUMA-12 3 year followup @BloodJournal

75% 3-year progression free survival

ashpublications.org/blood/articl...

Randomised ZUMA-23 data eagerly awaited

#lymsm #lymphoma

Just out at JAMA Oncology, led by Parsa Erfani

We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity

jamanetwork.com/journals/jam...

Just out in Nature Reviews Clinical Oncology: we explain why ibrutinib's mantle cell lymphoma indication should *not* have been withdrawn, dissect SHINE & TRIANGLE trial results & suggest what the FDA could have done instead rdcu.be/dmGJu
#healthpolicy #lymsm #mmsm